|
1. Biologie
|
|
|
|
|
2. Etiologie
|
|
|
|
3.1 Prévention - Tabac
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
5. Traitements
|
|
|
Fewer Flashy Drug Delivery Papers, Please [In the Pipeline]
|
|
|
|
|
|
The
work is conceptually quite interesting and seems to hold a lot of
potential, but you know, it has been some years now since this stuff
started to appear, and the number of these things that have made a dent
in the real world is small.
|
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
Former GSK boss to lead new UK accelerated drug access scheme [Reuters]
|
|
|
|
|
|
Drugmakers
will be expected to deliver “additional value for the taxpayer”, with a
new commercial unit being created within NHS England to help negotiate
cost-effective deals. Witty will lead the group responsible for deciding
which products should be granted breakthrough status, drawing on advice
from patients, clinicians and industry.
|
|
|
|
|
|
|
5.6 ESMO
|
|
|
|
5.8.2 ASH - Pharma
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
|
|
6.11 Patients
|
|
|
|
6.2 Implants mammaires
|
|
|